QuidelOrtho Showcases Innovation in Transfusion Medicine at AABB 2025 Annual Meeting

QuidelOrtho Reinforces Leadership in Transfusion Medicine at AABB 2025 Annual Meeting

QuidelOrtho Corporation, a key player in the in vitro diagnostics sector, showcases its commitment to advancing transfusion medicine at the AABB 2025 Annual Meeting. The spotlight is on the recent FDA approval of the Micro Typing Systems (MTS) DAT Card, a significant addition to QuidelOrtho's already robust portfolio in direct antiglobulin testing and immunohematology. This innovative product enhances the effectiveness of transfusion practices by providing a gel-based solution that works seamlessly with the ORTHO VISION™ Platform. The integration of column agglutination technology with sophisticated software capabilities, such as reflex testing and quality control, positions laboratories to deliver faster and more reliable results—critical factors for timely transfusion decisions.

Michelle Mullens, Global Product Manager for Portfolio Solutions in Transfusion Medicine at QuidelOrtho, emphasizes that the company’s presence at the AABB Annual Meeting underscores its dedication to innovation in laboratory performance and operational efficiency. By focusing on advancements that improve patient outcomes globally, QuidelOrtho aims to address the pressing needs of healthcare professionals and patients alike. The importance of these developments is magnified in a setting that gathers leading experts in blood and biotherapies, indicating a collective focus on enhancing transfusion practices through cutting-edge technology.

The AABB Annual Meeting also features a variety of educational sessions, including discussions about the complexities surrounding Rh(D) antigen identification—an ongoing challenge in transfusion medicine. QuidelOrtho's recent FDA approval and its commitment to expanding its offerings signal a transformative potential within the field. As the company continues to innovate, it is poised to significantly influence healthcare delivery for patients who depend on blood transfusions, ensuring that advancements in technology lead to better clinical outcomes.

In addition to its product innovations, QuidelOrtho’s active participation in industry events like the AABB Annual Meeting highlights its strategic approach to engaging with thought leaders and stakeholders in the transfusion medicine space. This engagement is crucial for understanding the evolving landscape of healthcare needs, particularly as transfusion practices become increasingly sophisticated.

As QuidelOrtho continues to pioneer solutions that enhance laboratory capabilities, it remains dedicated to fostering advancements that improve the quality of care for patients globally. The combination of technological innovation and strategic collaboration positions the company to take a leading role in the future of transfusion medicine.